Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07

Last abstract of #ACR23 was #ACRBest Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis Great performance, even with seroneg RA A blood test to: diagnose ?phenotype ?identify best b/tsDMARD Could be massive Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe

#ACRbest Yrin Preview @ACRheum J Bathon Take home Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c AI to read joint erosions on X-ray May be ‘too little too late’ #Steroids in #RA increase #MACE even after d/c #ACR23 @RheumNow

Identifying GCA diagnosis and disease activity through proteomics from plasma: diagnosis looks good disease activity looks harder (Much like a lot of things in GCA, really) Exciting work @MayoClinic @MdWarrington @jsung0906 #ACR23 ABST2601 @RheumNow https://t.co/SwxN58LieB

#ACR23 Yr in Preview J Bathon Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present dependent on how you ask the questions Unmet needs (I think 🤔) biomarkers of flare for #inflammatory #arthritis Rx select’n/retention @RheumNow

Is MSOT the New Ultrasound? Dr. Aurelie Najm reports on oral abstract 0750 presented at #ACR23 https://t.co/okbGHTR0i3 https://t.co/9zkHPiFl74

• Is MSOT the New Ultrasound? | RheumNow

Lupus Topic Panel https://t.co/w9eaxAzBNi

• Dr. John Cush

Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23 https://t.co/avnarOGZui https://t.co/4CeAumv31b

• Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis | Rheu…

Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn

Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU

#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg

A randomised clinical trial show improvements in clinical outcomes CDAI, VAS for both the ITIS diet and the Med diet. Baseline differences in the microbiome between responders and non-responders were seen. Sala Climent M, Abst#2124 #ACR23 @RheumNow https://t.co/tiyNcV7cmD https://t.co/EEP4zrwjXs

Abstract 2583 at #ACR23 👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline levels of peripheral blood lymphocyte sub-populations: ⭐️High % of B cell and low % of NK cells increase the probability of developing arthritis in ACPA + pts… https://t.co/3KEOI4eul0 https://t.co/irX6InWMbl

Large French study on infection risk of PsA biologics 12k pts over 6 years When compared to Humira, only Enbrel and Stelara had lower infection risk Concurrent steroid use associated with increased infection 1.85HR @RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl

Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without observed numbness occurring, focal lymphocytic sialadenitis in 20%, with a focus score >1 for 62%. Hugle T, Abst#2190 #ACR23 @RheumNow https://t.co/VYKdQw2YlC https://t.co/dWLWj2AdkI